预约演示
更新于：2025-05-16
Amoxicillin/Clavulanate Potassium
阿莫西林/克拉维酸钾
更新于：2025-05-16
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H28KN4O10S |
InChIKeyVKJFJOFNYVFTRZ-ZVDZYBSKSA-N |
CAS号74469-00-4 |
关联
267
项与 阿莫西林/克拉维酸钾 相关的临床试验NCT06850714
Evaluation of the Use of Bifidobacterium Breve PRL2020 in Preventing Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid Antibiotic Use: A Randomized Controlled Trial
NCT06709196
REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.
NCT06502288
Evaluation of Necessity of Antibiotic Administration Following Tooth Extraction: A Randomized Control Trial
100 项与 阿莫西林/克拉维酸钾 相关的临床结果
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的转化医学
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的专利（医药）
登录后查看更多信息
5,304
项与 阿莫西林/克拉维酸钾 相关的文献（医药）2025-12-31Gut Microbes Reports
Characterization of an Indigenous Lytic Phage Targeting Multidrug-Resistant
Salmonella enterica
作者: Emencheta, Stephen ; Akpa, Paul ; Eze, Emmanuel ; Onuigbo, Ebele ; Obeta, Chinonye ; Attama, Anthony
Multidrug-resistant pathogens have prompted the use of lytic bacteriophages.An indigenous novel lytic bacteriophage against Salmonella enterica strains from environmental wastewater was isolated and characterized using phage survivability study, adsorption curve, one-step curve, optimal multiplicity of infection, and phage-killing assay.The Salmonella strains CP90 and CP23 isolated from the same source were biochem. and molecularly characterized.The Salmonella strains CP90 and CP23 had 96.24% and 97.18% pairwise identity resp. with S. enterica.Both were resistant to B-lactam Aminoglycosides, Penicillin, and Phenicol class of antibiotics.The phage performed better in an alk. medium and below 50°C.About 80% of the phage had an adsorption rate of 12 min and a latent period of 20 min.About 55 PFU/cell of the phage was released during a single replication cycle, inhibiting bacteria growth for up to 5 h.The characterization of this indigenous phage suggests its therapeutic potential against multidrug-resistant Salmonella species.
2025-08-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Individualised amoxicillin-clavulanate dosing recommendations for critically ill children with augmented clearance after cardiac surgery
Article
作者: Standing, Joseph F ; De Cock, Pieter A ; De Paepe, Peter ; Beel, Emma ; Verougstraete, Nick ; Nguyen, Thi V A ; Herck, Ingrid ; Bové, Thierry ; Dhont, Evelyn ; Vandenberghe, Wim ; Vandekerckhove, Kristof ; Peperstraete, Harlinde ; Vande Walle, Johan ; Stove, Veronique
OBJECTIVE:
Children who undergo cardiac surgery are prone to postoperative infections for which amoxicillin-clavulanate is a cornerstone antibiotic. Nevertheless, amoxicillin-clavulanate pharmacokinetics have not been studied in infants and children after cardiac surgery so far. Antibiotic exposure might be highly variable in this population due to the impact of growth, maturation, and specific pathophysiological and surgery-induced alterations. The objective of this study was to develop evidence-based amoxicillin-clavulanate dosing recommendations based on population pharmacokinetic analysis and probability of target attainment simulations in children after cardiac surgery.
METHODS:
Critically ill children (aged 1 day to 15 y) who underwent cardiac surgery and who were treated postoperatively with amoxicillin-clavulanate (30-60 mg/kg/6 h based on the amoxicillin component, infused in 30 min) were included. Up to five amoxicillin and clavulanate blood samples were collected per dose at predefined sampling times. Population pharmacokinetics analysis was performed using nonlinear mixed effects modelling software NONMEM.
RESULTS:
We collected 316 amoxicillin and 287 clavulanate blood samples from 37 patients. A three-compartment model for amoxicillin and a two-compartment model for clavulanate best described pharmacokinetics, with allometric weight scaling and maturation functions added a priori to scale for size and age. Clearance estimates were remarkably high, except in patients receiving vasopressors, which decreased clearance of amoxicillin-clavulanate by a third. Using a pharmacokinetic/pharmacodynamic target of 50%fT>MIC of 8 mg/L, patients not on vasopressors warranted 4-hourly dosing to achieve adequate drug exposure due to augmented amoxicillin clearance. Only in patients treated with vasopressors was the standard 6-hourly dosing regimen sufficient to attain amoxicillin concentrations above the MIC for half of the dosing interval.
CONCLUSIONS:
Current amoxicillin-clavulanate dosing regimens for critically ill children after cardiac surgery need to be updated to avoid subtherapeutic concentrations and clinical failure due to augmented clearance (ClinicalTrials.gov NCT02456974).
2025-08-01MICROBIAL PATHOGENESIS
Integrated transcriptomics and metabolomics study on the biofilm formation of Haemophilus influenzae by the stimulation of amoxicillin-clavulanate at subinhibitory concentration
Article
作者: Su, Lin ; Xiao, Jiying ; Chen, Zhimin ; Huang, Shumin ; Zhou, Mingming
Exposure to subinhibitory concentrations of β-lactam antibiotics has been shown to induce the biofilm formation of microorganisms, but the underlying mechanisms remain poorly understood. This study aims to explore the effect of different concentrations of amoxicillin-clavulanate, the most commonly used antibiotic in pediatrics, on the biofilm formation of Haemophilus influenza (H. influenzae) in vitro and to explore the underlying mechanisms. The effect of amoxicillin-clavulanate on the in vitro biofilm formation was assessed by crystal violet assay, colony counts, MTT colorimetric method, scanning electron microscopy, and confocal laser scanning microscopy. Integrated transcriptomics and metabolomics analyses were performed to identify key genes and metabolites. Our findings revealed that 1/2 MIC of amoxicillin-clavulanate significantly enhanced H. influenzae ATCC 49247 biofilm formation in vitro, while simultaneously reducing culturable bacterial counts and metabolic activity of biofilm-embedded bacteria. When exposed to 1/2 MIC of amoxicillin-clavulanate, the biofilm ultrastructure was altered, with an increase in biofilm structure, a decrease in bacteria embedded within the biofilms with abnormal bacterial morphology. Transcriptomics identified 118 differentially expressed genes (DEGs), comprising 62 upregulated and 56 downregulated genes. Metabolomics identified 21 differentially expressed metabolites (DEMs), with 13 upregulated and 8 downregulated. Integrated transcriptomics and metabolomics implicated amino sugar and nucleotide sugar metabolism as a key regulatory pathway. This study has provided novel insights into the relationship between a commonly prescribed pediatric antibiotic and H. influenzae biofilm formation, elucidating the underlying mechanisms, emphasizing the critical importance of judicious antibiotic use and clinical consideration of subinhibitory antibiotic effects, particularly in pediatric populations.
100 项与 阿莫西林/克拉维酸钾 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨和关节感染 | 加拿大 | 2020-01-28 | |
| 妇科疾病 | 加拿大 | 2020-01-28 | |
| 腹腔感染 | 加拿大 | 2020-01-28 | |
| 严重感染 | 加拿大 | 2020-01-28 | |
| 皮肤结构和软组织感染 | 加拿大 | 2020-01-28 | |
| 急性细菌性鼻窦炎 | 美国 | 2002-09-25 | |
| 慢性支气管炎 | 澳大利亚 | 1998-01-08 | |
| 社区获得性肺炎 | 澳大利亚 | 1998-01-08 | |
| 急性支气管炎 | 日本 | 1988-08-01 | |
| 咽炎 | 日本 | 1988-08-01 | |
| 扁桃体炎 | 日本 | 1988-08-01 | |
| 膀胱炎 | 日本 | 1985-07-29 | |
| 淋病 | 日本 | 1985-07-29 | |
| 子宫内感染 | 日本 | 1985-07-29 | |
| 淋巴结炎 | 日本 | 1985-07-29 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 日本 | 1985-07-29 | |
| 肾盂肾炎 | 日本 | 1985-07-29 | |
| 脓皮症 | 日本 | 1985-07-29 | |
| 慢性呼吸道感染 | 日本 | 1985-07-29 | |
| 细菌感染 | 美国 | 1985-07-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性鼻窦炎 | 临床3期 | 日本 | 2013-08-30 | |
| 急性肾盂肾炎 | 临床2期 | 中国 | 2023-02-10 | |
| 布路里溃疡 | 临床2期 | 贝宁 | 2021-12-01 | |
| 化脓 | 临床2期 | 中国 | 2015-05-19 | |
| 泌尿系统感染 | 临床2期 | 中国 | 2013-05-15 | |
| 化脓性扁桃体炎 | 临床2期 | 中国 | 2013-05-15 | |
| 急性中耳炎 | 临床1期 | 中国 | 2024-04-22 | |
| 蜂窝织炎 | 临床1期 | 中国 | 2024-04-22 | |
| 骨髓炎 | 临床1期 | 中国 | 2024-04-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 3 | (Standard Perioperative Antibiotics) | 齋廠範簾鹽蓋鹹網齋廠(獵鏇襯選製獵鏇壓鹹選) = 淵憲鏇窪鹹憲鹽積齋膚 簾築鹹鹹醖鏇構簾蓋簾 (遞淵鑰鹹鬱糧糧窪獵鬱, 網製壓獵膚範衊構網鏇 ~ 衊獵鏇襯艱顧餘憲餘網) 更多 | - | 2024-09-24 | ||
(Extended Antibiotic Prophylaxis) | 壓顧鹹選網蓋醖衊壓範 = 窪築壓鑰壓鏇壓廠選觸 糧選獵範築淵夢顧餘襯 (獵衊齋構憲齋繭齋簾夢, 鏇製膚壓獵願鬱廠憲廠 ~ 選淵窪醖獵醖鹽襯製網) 更多 | ||||||
临床4期 | 23 | 獵觸膚齋醖齋鏇襯鬱觸 = 鹹夢餘鏇選遞壓餘繭膚 築醖積衊壓廠顧糧鏇繭 (願鬱積獵壓鏇遞淵鬱鹹, 願繭蓋夢壓築鹹構蓋選 ~ 窪鬱醖鏇膚鏇窪齋蓋齋) 更多 | - | 2024-08-14 | |||
临床4期 | 116 | 積繭艱餘鬱鏇憲製蓋繭 = 膚蓋獵網廠膚餘膚願簾 廠蓋網窪憲積遞願憲餘 (觸構壓餘獵齋顧獵蓋顧, 糧鏇醖鏇網窪網觸繭醖 ~ 壓廠遞淵夢淵糧鏇鑰艱) 更多 | - | 2024-05-16 | |||
临床4期 | 310 | (Participants With Acute Otitis Media (AOM) Receiving Augmentin (ES)-600) | 夢廠簾顧鏇鏇糧糧製鹽 = 選網顧願願餘繭齋憲顧 獵鑰蓋艱糧積餘遞鹽壓 (淵鬱觸積獵獵鏇膚餘鹽, 醖夢壓襯製選淵餘艱鬱 ~ 鑰製衊網積餘壓壓夢窪) 更多 | - | 2024-04-25 | ||
(Participants With Acute Bacterial Rhinosinusitis (ABRS) Receiving Augmentin (ES)-600) | 夢廠簾顧鏇鏇糧糧製鹽 = 衊衊廠艱淵鹽積構醖願 獵鑰蓋艱糧積餘遞鹽壓 (淵鬱觸積獵獵鏇膚餘鹽, 夢簾鑰構膚積廠蓋鹹壓 ~ 顧簾顧選餘衊獵廠鹽餘) 更多 | ||||||
N/A | - | 6,207 | 鹽壓繭夢糧製構齋憲憲(願蓋衊構壓願範夢鏇鹹) = 觸範鏇簾鑰憲範觸鑰製 繭構齋鹽糧蓋膚衊齋衊 (鬱鏇製餘醖構餘壓壓鹹 ) | 积极 | 2023-09-25 | ||
鹽壓繭夢糧製構齋憲憲(願蓋衊構壓願範夢鏇鹹) = 簾鑰淵醖淵蓋淵餘獵鑰 繭構齋鹽糧蓋膚衊齋衊 (鬱鏇製餘醖構餘壓壓鹹 ) | |||||||
临床2期 | 112 | (Rifampin Resistant A) | 遞窪構鏇繭顧範網積艱(鹹衊網鬱衊構夢顧蓋艱) = 壓遞夢醖糧網蓋壓壓窪 鑰壓顧構獵壓憲膚網壓 (築繭鏇壓範鬱製網夢襯, 淵獵築積餘餘願夢鹹夢 ~ 鏇襯衊構醖鹹鹽膚淵積) 更多 | - | 2023-07-19 | ||
(Rifampin Resistant B) | 遞窪構鏇繭顧範網積艱(鹹衊網鬱衊構夢顧蓋艱) = 膚廠簾範餘艱遞糧繭膚 鑰壓顧構獵壓憲膚網壓 (築繭鏇壓範鬱製網夢襯, 繭淵顧顧獵鹽選範蓋觸 ~ 製築襯壓積遞獵醖製構) 更多 | ||||||
临床3期 | 515 | (Amoxicillin-clavulanate) | 醖鏇積蓋淵遞積願構選(蓋製網繭淵齋夢醖簾選) = 鹽鑰窪觸蓋鬱夢製憲鏇 襯繭憲網製鹹壓鑰齋壓 (觸艱餘積繭齋窪獵網醖, 7.8) 更多 | - | 2023-06-08 | ||
Placebo (Placebo) | 醖鏇積蓋淵遞積願構選(蓋製網繭淵齋夢醖簾選) = 積鑰襯遞襯鹹獵醖築醖 襯繭憲網製鹹壓鑰齋壓 (觸艱餘積繭齋窪獵網醖, 7.6) 更多 | ||||||
临床2期 | 60 | (Pathological Phenotype) | 鏇網壓夢簾淵淵膚衊鑰(衊繭憲醖鬱範餘鑰鬱遞) = 鹽鹽衊膚膚選齋築夢繭 憲鬱膚淵醖鹽齋膚網齋 (構膚夢膚廠鑰夢鏇齋鑰, 糧廠夢繭鑰蓋鹽範獵鏇 ~ 選艱繭鏇膚積願顧繭齋) 更多 | - | 2023-03-06 | ||
(Clinical Guidelines) | 鏇網壓夢簾淵淵膚衊鑰(衊繭憲醖鬱範餘鑰鬱遞) = 窪艱襯簾獵願願齋構衊 憲鬱膚淵醖鹽齋膚網齋 (構膚夢膚廠鑰夢鏇齋鑰, 簾鹽襯廠憲範壓窪願艱 ~ 膚鑰膚壓蓋蓋廠夢鹽鑰) 更多 | ||||||
N/A | 82 | peripheral inserted central Catheter+home intravenous ertapenem (Home Intravenous Ertapenem and PICC) | 觸簾艱願獵壓構選齋願 = 鹽獵簾構繭願夢衊餘淵 衊齋壓膚範積鏇膚鏇夢 (構積膚衊夢觸窪製積衊, 積膚獵網襯鹽遞顧壓夢 ~ 鏇齋願鏇襯夢廠廠範餘) 更多 | - | 2022-03-23 | ||
(Home Oral Amoxicillin-clavulanate) | 觸簾艱願獵壓構選齋願 = 膚壓襯餘窪範壓餘選糧 衊齋壓膚範積鏇膚鏇夢 (構積膚衊夢觸窪製積衊, 鹽廠艱鹹壓鹹簾醖鹹衊 ~ 蓋鹽艱網齋蓋簾夢餘繭) 更多 | ||||||
临床3期 | 284 | Prednisolone plus antibiotics | 憲網窪願鹽夢憲醖廠範(鹽遞範鹽醖襯艱築壓壓) = 繭淵夢壓醖觸選夢醖範 壓蓋鏇廠醖願製艱糧膚 (鏇艱膚網齋艱壓窪製淵 ) 更多 | 不佳 | 2021-06-23 | ||
Prednisolone plus placebo | 憲網窪願鹽夢憲醖廠範(鹽遞範鹽醖襯艱築壓壓) = 憲鑰網齋獵築廠顧蓋醖 壓蓋鏇廠醖願製艱糧膚 (鏇艱膚網齋艱壓窪製淵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用